Abstract: Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.

Abstract: Substituted piperidines of formulae (I) and (II) with the substituent definitions as explained in the specification. The compounds are suitable in particular as renin inhibitors and are highly potent.

Abstract: Compounds of the general formula (I) in which R is heterocyclyl which is bonded via a carbon atom and is mono- or polysubstituted by C1-6-alkyl, trifluoromethyl, nitro, amino, C1-6-alkylamino, di-C1-6-alkylamino, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, C1-6-alkylcarbonyloxy, C0-6-alkylcarbonylamino, C1-6-alkoxycarbonylamino, hydroxyl, halogen, oxide, cyano, optionally N-mono- or N,N-di-C1-8-alkylated carbamoyl, optionally esterified carboxyl or C1-6-alkylenedioxy, or is substituted by oxo and mono- or polysubstituted by C1-6-alkyl, trifluoromethyl, nitro, amino, C1-6-alkylamino, di-C1-6-alkylamino, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, C1-6-alkylcarbonyloxy, C0-6-alkylcarbonylamino, C1-6-alkoxycarbonylamino, hydroxyl, halogen, oxide, cyano, optionally N-mono- or N,N-di-C1-8-alkylated carbamoyl, optionally esterified carboxyl or C1-6-alkylenedioxy, and salts, especially pharmaceutically usable salts have renin-inhibiting properties and can be used as medicaments.

Abstract: Compounds of the general formula (I) in which the substituents R, R1, R2, R3, R4, R5 and R6 are each as defined in claim 1 have renin-inhibiting properties and can be used as medicaments.

Abstract: The application relates to novel heterocyclic compounds of the general formula (I) (I*) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aromatase inhibitors.

Abstract: The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Abstract: The application relates to novel substituted piperidines of the general formula (I) in which R1, R2, R3, R4, W, X, Z, m and n are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

Abstract: The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

Abstract: The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Abstract: The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, W, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Abstract: Use of compounds of the general formula (I) and pharmaceutically acceptable salt thereof, in which R1, R2, R3, R4, W, X and Z, n and m have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

Abstract: The application relates to novel amino alcohols of the general formula (I) where R, R1, R2, R3, R4, R5 and R6 each have the definitions illustrated in detail in the description, to a process for their preparation, and to the use of these compounds as medicines, in particular as renin inhibitors.

Abstract: The application relates to novel amino alcohols of general formula (I) where R, R1, R2, R3, R4, R5,X1 and X2 each have the definitions illustrated in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

Abstract: Use of compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6 and X have the definitions elucidated in more detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

Abstract: Use of compounds of the general formula (I) or a pharmaceutically usable salt thereof; wherein R1, R2, R3, R4, R5 and X have the definitions elucidated in more detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

Abstract: Use of compounds of the general formula (I) in which R, R1, R2, R3, R4, R5, and R6 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

Abstract: Use of compounds of the general formula (I) in which R, R1, R2, R3, R4, R5, X1 and X2 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

Abstract: Use of compounds of the general formula (I) in which R, R1, R2, R3, R4, R5 and R6 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

Abstract: Novel substituted piperidines of the general formulae (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.

Abstract: A process for the preparation of 2(S)-alkyl-5-halogenpent-4-ene carboxylic esters by enzymatic hydrolysis, comprising the steps: a) enzymatic hydrolysis of racemic 2-alkyl-5-halogenpent-4-ene carboxylic esters in aqueous and alkaline medium in the presence of an esterase; b) isolation of 2(S)alkyl-5-halogenpent-4-ene carboxylic esters by extraction with an organic solvent; c) isolation of 2(R)-alkyl-5-halogenpent-4-ene carboxylic acids from the aqueous-alkaline medium; d) Esterification of 2(R)-alkyl-5-halogenpent-4-ene carboxylic acids, e) subsequent racemization to form 2-alkyl-5-halogenpent-4-ene carboxylic esters; and f) return of the racemate obtained in step e) to step a), if necessary together with fresh racemic 2-alkyl-5-halogenpent-4-ene carboxylic esters. The process permits the undesired R-stereoisomers to be converted into the desired 2(S)-alkyl-5-halogenpent-4-ene carboxylic esters to avoid waste product from the synthesis.